Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges

Horace Massa,1,* Spyros Y Pipis,2,* Temilade Adewoyin,2 Athanasios Vergados,2 Sudeshna Patra,2 Georgios D Panos2,* 1Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland; 2Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK*These authors...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/ed598200caeb488bb2a0f4daa0acebe8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Horace Massa,1,* Spyros Y Pipis,2,* Temilade Adewoyin,2 Athanasios Vergados,2 Sudeshna Patra,2 Georgios D Panos2,* 1Department of Ophthalmology, Geneva University Hospitals, Geneva, Switzerland; 2Eye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, London, UK*These authors contributed equally to this workCorrespondence: Georgios D PanosEye Treatment Centre, Whipps Cross University Hospital, Barts Health NHS Trust, Whipps Cross Road, Leytonstone, E11 1NR London, UKTel +44 208 539 5522Email gdpanos@gmail.comAbstract: Macular edema (ME) is the most common sight-threatening complication in uveitis. The diagnostic and therapeutic management of the uveitic macular edema (UME) might be challenging due to the complex diagnostic workup and the difficulties physicians face to find the underlying cause, and due to its usually recurrent nature and the fact that it can be refractory to conventional treatment. Some of the mild cases can be treated with topical steroids, which can be combined with non-steroid anti-inflammatory drugs. However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.Keywords: non-infectious uveitis, macular edema, NSAIDs, anti-TNF alpha, corticosteroids, immunomodulators